URS
DNLI icon

Utah Retirement Systems’s Denali Therapeutics DNLI Stock Holding History

Utah Retirement Systems’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-11,600
Closed -$341K – 965
2022
Q2 		$341K Hold
11,600
– – 0.01% 861
2022
Q1 		$373K Hold
11,600
– – 0.01% 865
2021
Q4 		$517K Hold
11,600
– – 0.01% 854
2021
Q3 		$585K Sell
11,600
-900
-7% -$50.7K 0.01% 841
2021
Q2 		$981K Buy
12,500
+3,800
+44% +$235K 0.01% 791
2021
Q1 		$497K Buy
+8,700
New +$582K 0.01% 832

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Utah Retirement Systems's DNLI Position: Q3 2022 in Review

Utah Retirement Systems sold out of Denali Therapeutics (DNLI) in Q3 2022, closing a stake of 11,600 shares — an estimated $341K sold.

Utah Retirement Systems first reported a position in DNLI in Q1 2021 and held it in 6 quarters. The position peaked at $981K in Q2 2021. 200 funds tracked by Wall St. Rank hold DNLI as of Q3 2022.

  • Utah Retirement Systems reported no remaining Denali Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Utah Retirement Systems sold 11,600 Denali Therapeutics shares in Q3 2022, an estimated $341K.
  • Utah Retirement Systems first reported a position in Denali Therapeutics in Q1 2021 and held it in 6 quarters.
  • Utah Retirement Systems's Denali Therapeutics position peaked at $981K in Q2 2021.
  • 200 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2022.

Based on Utah Retirement Systems's 13F filing for Q3 2022, filed 14 Nov 2022.